Response to immune checkpoint inhibitors in acral melanoma: A nationwide cohort study
-
Published:2022-05
Issue:
Volume:167
Page:70-80
-
ISSN:0959-8049
-
Container-title:European Journal of Cancer
-
language:en
-
Short-container-title:European Journal of Cancer
Author:
van Not Olivier J., de Meza Melissa M., van den Eertwegh Alfons J.M., Haanen John B., Blank Christian U., Aarts Maureen J.B., van den Berkmortel Franchette W.P.J., van Breeschoten JesperORCID, de Groot Jan-Willem B., Hospers Geke A.P., Ismail Rawa K., Kapiteijn Ellen, Piersma Djura, van Rijn Roos S., Stevense-den Boer Marion A.M., van der Veldt Astrid A.M., Vreugdenhil Gerard, Bonenkamp Han J., Boers-Sonderen Marye J., Blokx Willeke A.M., Wouters Michel W.J.M., Suijkerbuijk Karijn P.M.
Subject
Cancer Research,Oncology
Reference32 articles.
1. Five-Year survival with combined nivolumab and ipilimumab in advanced melanoma;Larkin;N Engl J Med,2019 2. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study;Robert;Lancet Oncol,2019 3. Real-world outcomes of first-line anti-PD-1 therapy for advanced melanoma: a nationwide population-based study;Van Zeijl;J Immunother,2020 4. Melanoma epidemiology, biology and prognosis;Ali;Eur J Canc Suppl,2013 5. Acral lentiginous melanoma;Piliang;Clin Lab Med,2011
Cited by
24 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|